Ketoconazole

Ketoconazole is a synthetic antifungal drug belonging to the imidazole subclass of the azole antifungals ^[1]. When it was introduced it was notable for being the first azole antifungal that could be taken by mouth to treat infections throughout the body, whereas earlier azoles were limited to topical use ^[1]. Chemically it is a racemic mixture of two mirror-image forms, and it possesses antiandrogen and antiglucocorticoid properties in addition to its antifungal action ^[2].

The compound was discovered in 1976 by scientists at the Belgian company Janssen Pharmaceutica, patented the following year, and introduced in the United States in 1981 ^[1]. It is marketed under the brand name Nizoral, among others, and remains in common use, chiefly in its topical forms ^[1].

Ketoconazole treats a range of fungal conditions. Topically, as a cream or as a medicated shampoo, it is used for fungal skin infections, tinea versicolor, and, very commonly, for dandruff and seborrheic dermatitis, conditions linked to the scalp yeast Malassezia ^[1][4]. It has also attracted off-label interest as an adjunct in androgenetic hair loss, where its effects on the scalp and on local hormone activity are thought to play a role ^[4][5]. Taken by mouth in higher doses, its ability to shut down steroid production has been used to treat Cushing's syndrome and advanced prostate cancer, and it can suppress excess hair growth in hirsutism ^[2][3].

At the molecular level the drug blocks the fungal enzyme that makes ergosterol, undermining the fungal cell membrane, while its inhibition of related human enzymes accounts for its hormonal effects and many drug interactions ^[1][2]. This dual character, useful against fungi but disruptive to the body's own enzyme systems, shaped how the drug came to be used ^[2].

The most serious concern with oral ketoconazole is liver toxicity, which was recognized within a few years of its approval and, together with its endocrine effects and interactions, led regulators to act decisively ^[1]. In 2013 oral ketoconazole was suspended in the European Union and Australia and sharply restricted in the United States and Canada, so that systemic use is now reserved for certain serious fungal infections when better options are unavailable ^[1]. Topical preparations, including creams and 1 to 2 percent shampoos, are not associated with liver injury and remain widely available and regarded as safe ^[1][4].

Topical ketoconazole is available over the counter at lower strength and by prescription at higher strength, and it is generally well tolerated. Local effects include scalp or skin irritation, dryness, itching and occasional changes in hair texture, with rare contact allergy. Very little is absorbed through intact skin, so the hepatotoxicity and hormone effects seen with oral ketoconazole are not a concern with the topical forms. It is for external use only and should be kept out of the eyes.

Ketoconazole is a potent, broad-spectrum inhibitor of hepatic CYP3A4. Substrates of CYP3A4 show marked exposure increases when co-administered with ketoconazole; more sensitive substrates like some statins or certain immunosuppressants show 5- to 18-fold increases in plasma concentration ^[7]. This is a pharmacokinetic mechanism where ketoconazole inhibits the metabolism of victim drugs, elevating their levels and risk of toxicity. The interaction is directional; ketoconazole affects substrate levels far more than substrates affect ketoconazole clearance.

Ketoconazole also inhibits some P-glycoprotein efflux transporters, compounding exposure increases for dual substrates. Quantitatively, CYP3A4 substrates with high hepatic extraction are most vulnerable; drugs with extra-hepatic clearance paths show smaller interactions. Interactions with mild to moderate CYP3A4 inhibitors (such as erythromycin or diltiazem) and with CYP3A4 inducers (rifampin, St. John's Wort) remain relevant but have not been as systematically documented.

Checking a whole stack? Run it through interactions + stacks.

Ketoconazole was developed by the Belgian company Janssen Pharmaceutica and introduced in the early 1980s as the first orally active azole antifungal, a milestone that opened the door to systemic treatment of fungal infection by mouth. Chemically an imidazole, it works by blocking the fungal enzyme lanosterol 14-alpha-demethylase (CYP51) and thus the synthesis of ergosterol, the sterol that maintains the integrity of the fungal cell membrane.

Early pharmacological studies soon revealed that, at higher doses, it also inhibits human cytochrome P450 enzymes involved in steroid-hormone synthesis, a property later exploited in Cushing's syndrome and prostate cancer and explored off-label in hormone-driven hair loss. Because of a recognized risk of serious liver injury, oral ketoconazole was subsequently restricted in many countries and reserved for limited indications. Its topical forms, however, remained widely used and well tolerated, including medicated shampoos for dandruff and seborrheic dermatitis sold under names such as Nizoral. In these applications it endures as a familiar and dependable antifungal.

Ketoconazole enjoys a durable reputation, particularly in topical form, as a reliable and accessible antifungal for scalp and skin conditions. As a medicated shampoo it is a first-line remedy for dandruff and seborrheic dermatitis, valued for reducing the Malassezia yeast that drives these conditions along with the associated flaking and inflammation.

It has also attracted a devoted following in the hair-loss community, where small studies suggest topical use may modestly reduce shedding and even support hair density, plausibly through combined antifungal, anti-inflammatory, and mild anti-androgen effects on the scalp. Its historical importance as the first oral azole is considerable. In fairness, the oral form's potential for liver injury and hormonal side effects has appropriately narrowed its systemic use, and its precise benefits for hair remain incompletely proven. As a topical agent, however, it is inexpensive, effective, and time-tested.